Business
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue
Total preliminary 4Q and full year 2025 net product revenue of $196.0 million and $638.5 million, respectively, representing 65% and 66% annual growth,
About this update from Axsome Therapeutics, Inc.
[{"type":"text","content":"Total preliminary 4Q and full year 2025 net product revenue of $196.0 million and $638.5 million, respectively, representing 65% and 66% annual growth, respectively AUVELITY® preliminary 4Q and full year 2025 net product sales of $155.1 million and $507.1 million, respectively SUNOSI® preliminary 4Q and full year 2025 net product revenue of $36.7 million and $124.8 million, respectively SYMBRAVO® preliminary 4Q and full year 2025 net product sales of $4.1 million and $6.6 million, respectively NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced preliminary fourth quarter and full year 2025 net product revenues for AUVELITY, SUNOSI, and SYMBRAVO. Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue (Unaudited) Based on preliminary unaudited financial information, Axsome expects total product revenue to be approximately $196.0 million for the fourth quarter, representing 65% annual growth compared to the fourth quarter 2024, and approximately $638.5 million for the full year 2025, representing 66% annual growth compared to the full year 2024. AUVELITY net product sales are expected to be approximately $155.1 million and $507.1 million for the fourth quarter and full year 2025, respectively.SUNOSI net product revenue is expected to be approximately $36.7 million and $124.8 million for the fourth quarter and full year 2025, respectively.SYMBRAVO net product sales are expected to be approximately $4.1 million and $6.6 million for the fourth quarter and full year 2025, respectively, following its commercial launch in June 2025. The foregoing information reflects the Company's estimates with respect to net product revenues for AUVELITY, SUNOSI, and SYMBRAVO based on currently available unaudited information. This announcement is not a comprehensive statement of Axsome’s financial results and is subject to completion of Axsome’s financial closing procedures. Axsome’s final financial results will be issued upon completion of its closing procedures and may vary from these preliminary estimates. About Axsome Therapeutics Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific bre...